Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
broussonetia + lonicera
- Development stage
- Unknown
- Lead developer
- PharmaKing
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
PMK N02RS1 (broussonetia + lonicera) is a botanical combination drug developed by PharmaKing for the treatment of acute bronchitis and acute exacerbations of chronic bronchitis. The formulation consists of a 1:1 mixture of the ethyl acetate fraction from the root barks of *Broussonetia papyrifera* and a 70% aqueous ethanol extract from the whole plants of *Lonicera japonica*. Its therapeutic mechanism involves the dual inhibition of 5-lipoxygenase (5-LOX), which reduces leukotriene production, and the down-regulation of key proinflammatory cytokines, including TNF-α, IL-1, IL-6, and IFN-γ. The drug has been evaluated in Phase 2 clinical trials in South Korea to assess its efficacy and safety using the Bronchitis Severity Score (BSS).
- Other names
- Broussonetia and Lonicera extractBroussonetia papyrifera and Lonicera japonica extract
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ALOX5 (Arachidonate 5-lipoxygenase)TNFA (Tumor necrosis factor alpha (soluble))NOS2 (Nitric Oxide Synthase 2)IL-6 (Interleukin 6)MMP2 (Matrix metalloproteinase-2)IFNG (Interferon gamma)IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on broussonetia + lonicera.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on broussonetia + lonicera.